Risk factors for nosocomial infections caused by extended-spectrum β-lactamase producing escherichia coli or klebsiella pneumoniae in Thailand

Asian Biomedicine

Volumn 2, Issue 6, 2008, Pages 485-491

  Saonuam, Pairoj ^a   Hiransuthikul, Narin ^a   Suankratay, Chusana ^a   Malathum, Kumthorn ^b   Danchaivijitr, Somwang ^c  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Escherichia coli; Extended spectrum lactamases; Klebsiella pneumoniae; Nosocomial infections; Risk factors

Indexed keywords

AMINOGLYCOSIDE; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEPHALOSPORIN; CLINDAMYCIN; EXTENDED SPECTRUM BETA LACTAMASE; IMMUNOSUPPRESSIVE AGENT; METRONIDAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STEROID; VANCOMYCIN;

ADULT; ARTICLE; BACTERIAL STRAIN; CASE CONTROL STUDY; CONTROLLED STUDY; DEVICE INFECTION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; HOSPITAL INFECTION; HUMAN; INFECTION RISK; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; THAILAND;

EID: 67650666295     PISSN: 19057415     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Clinical and Laboratory Standards Institute. Performance Standard for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement. CLSI document M100-S16: Clinical and Laboratory Standards Institute, Wayne, Pennsylvania 19087-198, USA, 2006.
2. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008; 8: 159-166.
3. Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol. 2006; 27:1226-1232.
4. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001; 32:1162-1171.
5. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y Clinical and economic impact of bacteremia with extended-spectrum-beta- lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2006; 50:1257-1262.
6. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005; 18:657-686.
7. Sturenburg E, Mack D. Extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control. J Infect. 2003; 47:273-295.
8. Shah AA, Hasan F, Ahmed S, Hameed A. Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum beta-lactamases. Res Microbiol. 2004; 155:409-421.
9. Rahal JJ, Urban C, Horn D, Freeman K, Segal-Maurer S, Maurer J, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. Jama. 1998; 280:1233-1237.
10. Lan CK, Hsueh PR, Wong WW, Fung CP, Lau YT, Yeung JY, et al. Association of antibiotic utilization measures and reduced incidence of infections with extended-spectrum beta-lactamase-producing organisms. J Microbiol Immunol Infect. 2003; 36:182-186.
11. Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, Mundy LM. Risk factors for and outcomes of healthcare-associated infection due to extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae in Thailand. Infect Control Hosp Epidemiol. 2007; 28:873-876.
12. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988; 16:128-140.
13. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40:373-383.
14. Kanafani ZA, Mehio-Sibai A, Araj GF, Kanaan M, Kanj SS. Epidemiology and risk factors for extended-spectrum beta-lactamase-producing organisms: a case control study at a tertiary care center in Lebanon. Am J Infect Control. 2005; 33:326-332.
15. Graffunder EM, Preston KE, Evans AM, Venezia RA. Risk factors associated with extended-spectrum beta-lactamase-producing organisms at a tertiary care hospital. J Antimicrob Chemother. 2005; 56:139-145.
16. Du B, Long Y, Liu H, Chen D, Liu D, Xu Y, et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med. 2002; 28:1718-1723.
17. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial infections. Ann Intern Med. 2004; 140:26-32.
18. McGregor JC, Kim PW, Perencevich EN, Bradham DD, Furuno JP, Kaye KS, et al. Utility of the Chronic Disease Score and Charlson Comorbidity Index as comorbidity measures for use in epidemiologic studies of antibiotic-resistant organisms. Am J Epidemiol. 2005; 161:483-493.
19. Kang CI, Kim SH, Kim DM, Park WB, Lee KD, Kim HB, et al. Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2004; 25:860-867.
20. Bellissimo-Rodrigues F, Gomes AC, Passos AD, Achcar JA, Perdona Gda S, Martinez R. Clinical outcome and risk factors related to extended-spectrum beta-lactamase-producing Klebsiella spp. infection among hospitalized patients. Mem Inst Oswaldo Cruz. 2006; 101:415-421.
21. Kaye KS, Harris AD, Samore M, Carmeli Y. The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect Control Hosp Epidemiol. 2005; 26:346-351.